138 related articles for article (PubMed ID: 12869082)
1. Economic analysis of celecoxib versus diclofenac plus omeprazole for the treatment of arthritis in patients at risk of ulcer disease.
Lee KK; You JH; Ho JT; Suen BY; Yung MY; Lau WH; Lee VW; Sung JY; Chan FK
Aliment Pharmacol Ther; 2003 Jul; 18(2):217-22. PubMed ID: 12869082
[TBL] [Abstract][Full Text] [Related]
2. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.
Chan FK; Hung LC; Suen BY; Wu JC; Lee KC; Leung VK; Hui AJ; To KF; Leung WK; Wong VW; Chung SC; Sung JJ
N Engl J Med; 2002 Dec; 347(26):2104-10. PubMed ID: 12501222
[TBL] [Abstract][Full Text] [Related]
3. Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents.
You JH; Lee KK; Chan TY; Lau WH; Chan FK
Aliment Pharmacol Ther; 2002 Dec; 16(12):2089-96. PubMed ID: 12452942
[TBL] [Abstract][Full Text] [Related]
4. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
Chan FK; Lanas A; Scheiman J; Berger MF; Nguyen H; Goldstein JL
Lancet; 2010 Jul; 376(9736):173-9. PubMed ID: 20638563
[TBL] [Abstract][Full Text] [Related]
5. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial.
Chan FK; Hung LC; Suen BY; Wong VW; Hui AJ; Wu JC; Leung WK; Lee YT; To KF; Chung SC; Sung JJ
Gastroenterology; 2004 Oct; 127(4):1038-43. PubMed ID: 15480981
[TBL] [Abstract][Full Text] [Related]
6. Celecoxib versus diclofenac and omeprazole to prevent recurrent ulcer bleeding.
Lanas A
N Engl J Med; 2003 Jun; 348(24):2464-6; author reply 2464-6. PubMed ID: 12802035
[No Abstract] [Full Text] [Related]
7. Celecoxib versus diclofenac and omeprazole to prevent recurrent ulcer bleeding.
Nurmohamed MT; Lems WF
N Engl J Med; 2003 Jun; 348(24):2464-6; author reply 2464-6. PubMed ID: 12803213
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial.
Kellner HL; Li C; Essex MN
Curr Med Res Opin; 2012 Sep; 28(9):1537-45. PubMed ID: 22852870
[TBL] [Abstract][Full Text] [Related]
9. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
[TBL] [Abstract][Full Text] [Related]
10. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial.
Chan FK; Wong VW; Suen BY; Wu JC; Ching JY; Hung LC; Hui AJ; Leung VK; Lee VW; Lai LH; Wong GL; Chow DK; To KF; Leung WK; Chiu PW; Lee YT; Lau JY; Chan HL; Ng EK; Sung JJ
Lancet; 2007 May; 369(9573):1621-6. PubMed ID: 17499604
[TBL] [Abstract][Full Text] [Related]
11. NSAIDs and risk of lower gastrointestinal bleeding.
Rahme E; Bernatsky S
Lancet; 2010 Jul; 376(9736):146-8. PubMed ID: 20638554
[No Abstract] [Full Text] [Related]
12. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.
Chan FKL; Ching JYL; Tse YK; Lam K; Wong GLH; Ng SC; Lee V; Au KWL; Cheong PK; Suen BY; Chan H; Kee KM; Lo A; Wong VWS; Wu JCY; Kyaw MH
Lancet; 2017 Jun; 389(10087):2375-2382. PubMed ID: 28410791
[TBL] [Abstract][Full Text] [Related]
13. Helicobacter pylori eradication prior to initiation of long-term non-steroidal anti-inflammatory drug therapy in Chinese patients-a cost-effectiveness analysis.
You JH; Lau W; Lee IY; Yung M; Ching JY; Chan FK; Lee KK
Int J Clin Pharmacol Ther; 2006 Apr; 44(4):149-53. PubMed ID: 16625983
[TBL] [Abstract][Full Text] [Related]
14. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
Spiegel BM; Targownik L; Dulai GS; Gralnek IM
Ann Intern Med; 2003 May; 138(10):795-806. PubMed ID: 12755551
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Silverstein FE; Faich G; Goldstein JL; Simon LS; Pincus T; Whelton A; Makuch R; Eisen G; Agrawal NM; Stenson WF; Burr AM; Zhao WW; Kent JD; Lefkowith JB; Verburg KM; Geis GS
JAMA; 2000 Sep; 284(10):1247-55. PubMed ID: 10979111
[TBL] [Abstract][Full Text] [Related]
16. Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands.
Al MJ; Maniadakis N; Grijseels EW; Janssen M
Value Health; 2008; 11(4):589-99. PubMed ID: 18194404
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.
Chancellor JV; Hunsche E; de Cruz E; Sarasin FP
Pharmacoeconomics; 2001; 19 Suppl 1():59-75. PubMed ID: 11280106
[TBL] [Abstract][Full Text] [Related]
18. Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis.
Cheung R; Cheng TT; Dong Y; Lin HY; Lai K; Lau CS; Feng H; Parsons B
Int J Rheum Dis; 2010 May; 13(2):151-7. PubMed ID: 20536600
[TBL] [Abstract][Full Text] [Related]
19. A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model.
Brereton N; Pennington B; Ekelund M; Akehurst R
J Med Econ; 2014 Sep; 17(9):677-84. PubMed ID: 24914585
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G
J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
